CD274 and renal cell carcinoma: In the bladder cancer dataset, 167 and 25 patients were classified as PD or CR, respectively (Mariathasan et al., 2018), and 26 and 9 in the renal cell carcinoma (RCC) cohort (McDermott et al., 2018) following monotherapy with anti-PD-L1.